Zubair Khalid

Virologist/Molecular Biologist | Veterinarian | Bioinformatician

Conventional & Molecular Virology • Vaccine Development • Computational Biology

Dr. Zubair Khalid is a veterinarian and virologist specializing in conventional and molecular virology, vaccine development, and computational biology. Dedicated to advancing animal health through innovative research and multi-omics approaches.

Dr. Zubair Khalid - Veterinarian, Virologist, and Vaccine Development Researcher specializing in Computational Biology, Multi-omics, Animal Health, and Infectious Disease Research

Category: Guides

Biomedical Genomics

Biomedical genomics is the study of an organism’s complete set of DNA (the genome) and its influence on health and disease, combining high-throughput sequencing, computational analysis, and clinical interpretation. This guide is written for graduate students, early-career researchers, and clinical bioinformaticians who need a practical, source‑bounded framework to design, execute, and critically evaluate genomic analyses in a biomedical setting. You will learn core concepts, decision points for study design, a step‑by‑step workflow, common pitfalls, and the inherent limits of genomic interpretation.

Understanding genomic data requires a clear grasp of the biological layers involved. The genome itself is stable, but its expression, regulation, and variation drive phenotypes. For example, a recent study examining the shared genetic architecture of problematic alcohol use and anxiety disorders used genome‑wide association data to identify pleiotropic loci, illustrating how genomics can uncover cross‑disorder mechanisms [6]. Elsewhere, researchers analyzed somatic mitochondrial DNA mutations in hepatocellular carcinoma and found that these mutations independently predict worse prognosis, a finding that depends on robust variant calling and validation [8]. These examples underscore why a rigorous analytical pipeline is essential. The NCBI Bookshelf provides authoritative technical references on genome assembly, annotation, and comparative genomics, making it an ideal starting point for foundational knowledge [1].

At a Glance

Core Concept Description Relevance in Biomedical Genomics
Genome Complete DNA sequence of an organism Reference for variant detection, structural variation
Transcriptome All RNA molecules expressed in a sample Gene expression, splicing, non‑coding RNA
Epigenome Chemical modifications on DNA and histones Regulation, imprinting, environmental response
Variant Calling Identification of differences from reference SNPs, indels, CNVs linked to disease
Functional Annotation Assigning biological meaning to genomic elements Prioritizing causal variants, pathway analysis
Population Genomics Genetic variation across groups Heritability, risk stratification, evolutionary medicine

Decision Criteria for a Biomedical Genomics Study

Before collecting a single sequencing read, you must decide on the study design and technology. These choices directly affect the quality and interpretability of your results.

Phenotype versus genotype first. If you start with a phenotype (e.g., a disease of unknown cause), a whole‑exome or whole‑genome sequencing approach is common. If you start with a known variant, a targeted panel may be more cost‑effective and yield higher depth.

Sequencing technology. Short‑read platforms (e.g., Illumina) dominate most applications because of low error rates and high throughput. Long‑read platforms (e.g., PacBio, Oxford Nanopore) better resolve repetitive regions and structural variants but have higher per‑base error rates. Your choice depends on the genomic feature under investigation.

Sample size and power. For association studies, larger sample sizes increase statistical power. However, for individual variant discovery in rare diseases, a family‑based design can be more informative. The EMBL‑EBI training resources offer courses on statistical genetics that cover power calculations and study design [2].

Reference genome version. Use the most recent human reference (currently GRCh38 or T2T‑CHM13) for alignment. Older references can cause mapping artefacts and missed variants. Ensure all downstream analyses use the same genome build.

Computational resources. Consider whether you will use local high‑performance computing, cloud platforms, or a graphical workflow system like the Galaxy platform. Galaxy provides open, reproducible tools and training modules for genomic data analysis [3].

Practical Workflow: From Sample to Interpretation

A typical biomedical genomics analysis follows a structured pipeline. Each stage has quality checks and decision points.

1. Sample Collection and Library Preparation

  • Action: Extract high‑molecular‑weight DNA or RNA. Prepare sequencing libraries with appropriate fragmentation and adapter ligation.
  • Quality check: Assess nucleic acid integrity (e.g., using a Bioanalyzer) and quantify with fluorometry. Low integrity yields poor data.
  • Source: The NCBI Sequence Read Archive (SRA) stores raw sequencing data from thousands of studies, you can browse SRA to see typical quality metrics and metadata [5].

2. Sequencing and Raw Data Handling

  • Action: Sequence on your platform of choice. Generate FASTQ files containing reads and their quality scores.
  • Decision: Determine whether paired‑end or single‑end reads are needed. Paired‑end data improves mapping and detection of structural variants.
  • Quality control: Run FastQC on raw reads. Filter low‑quality bases and remove adapter contamination with tools like Trimmomatic or cutadapt.

3. Alignment to a Reference Genome

  • Action: Use a splice‑aware aligner (e.g., STAR for RNA‑seq) or a general aligner (e.g., BWA‑MEM for DNA‑seq). Output a BAM file of aligned reads.
  • Quality check: Assess alignment statistics: percentage mapped, duplication rate, insert size distribution. High duplication may indicate PCR bias.
  • Source: Bioconductor provides dedicated R packages for reading and processing BAM files, such as Rsamtools and GenomicAlignments [4].

4. Post‑Alignment Processing

  • Action: Mark duplicates, recalibrate base quality scores (for DNA‑seq), and perform local realignment around indels.
  • Quality check: Visualize alignments in a genome browser (IGV) for a few genomic regions to confirm proper processing.

5. Variant Calling

  • Action: Use tools like GATK HaplotypeCaller, FreeBayes, or DeepVariant. For RNA‑seq, use variant callers that account for splicing.
  • Decision: Choose between germline or somatic calling algorithms. Somatic calling requires matched tumor‑normal pairs and specialized tools like Mutect2.
  • Quality check: Compare variant calls against known truth sets (e.g., Genome in a Bottle). Filter variants by depth, quality score, and allele frequency.

6. Variant Annotation and Prioritization

  • Action: Annotate variants with functional information: gene, transcript, consequence (missense, nonsense, splice), population frequency (gnomAD), and pathogenicity scores (CADD, PolyPhen).
  • Decision: Rank variants based on inheritance pattern, conservation, and biological plausibility. For example, a truncating mutation in a gene implicated in motor neuron function could be prioritized in amyotrophic lateral sclerosis research, echoing a recent study that showed nuclear condensates formed by truncated NEK1 impede ribosomal RNA biogenesis and drive motor dysfunction [10].
  • Source: EMBL‑EBI’s Ensembl VEP (Variant Effect Predictor) is a widely used annotation tool [2].

7. Downstream Analysis and Interpretation

  • Action: Perform enrichment analysis, pathway over‑representation, or polygenic risk score calculation. Integrate with other omics data (transcriptomics, epigenomics).
  • Quality check: Validate findings in independent cohorts or using orthogonal methods (e.g., Sanger sequencing).
  • Source: Bioconductor offers curated packages for enrichment testing (e.g., clusterProfiler) and genomic feature visualization [4].

Common Mistakes in Biomedical Genomics

Even experienced researchers make errors that compromise reproducibility and biological interpretation.

Ignoring batch effects. When processing multiple samples, technical variation from different reagent lots, sequencing runs, or handling dates can introduce systematic bias. Use principal component analysis (PCA) on expression data or genotype data to detect batch effects and include batch as a covariate in statistical models.

Inadequate read depth. For reliable variant calling in human whole‑genome sequencing, 30x coverage is a minimum. Lower depth increases false negatives, especially for heterozygous variants. For RNA‑seq, depth requirements vary by transcript abundance and research question.

Using outdated or incorrect reference. As noted, mismatched genome builds cause alignment errors. Always verify the reference used during alignment and annotation.

Overlooking repetitive regions. Short reads often fail to map uniquely in repeats, leading to gaps and false variant calls. Long‑read technologies or specialized tools (e.g., for mitochondrial DNA analysis) may be necessary. A study of brain mitochondria even highlighted their central role in cognition, underscoring the need for accurate mitochondrial genome analysis [7].

Confusing correlation with causation. Genetic associations do not automatically imply a causal variant. Additional functional studies and fine‑mapping are required. As one editorial on genome architecture and expression pointed out, understanding the three‑dimensional organization of the genome is crucial for linking variants to regulatory mechanisms [11].

Limits and Uncertainty in Genomic Interpretation

Biomedical genomics is powerful, but it has inherent boundaries.

Incomplete annotation. Many genes and regulatory elements remain poorly characterized. A variant classified as “variant of unknown significance” may become pathologic as knowledge grows. Functional validation is often necessary before clinical action.

Population bias. Most reference genomes and large‑scale databases are derived from European ancestry populations. Variants in other ancestries are underrepresented, leading to misclassification and inequitable clinical utility. A preprint on biosecurity in livestock farming highlights how environmental and genetic factors interact differently across populations, a lesson that applies to human genomics as well [9]. However, that study is not directly about human genomics, it is used here to emphasize the importance of context.

Technical limitations of short‑read sequencing. Large structural variants, repetitive expansions, and copy‑number variants in complex regions are difficult to detect accurately. Long‑read sequencing can address some of these gaps but at higher cost.

Interpretation of non‑coding variants. Most disease‑associated SNPs lie in non‑coding regions. Their functional impact is hard to predict, they may alter enhancers, promoters, or chromatin loops. Integrative analysis with epigenomics data (e.g., ATAC‑seq, ChIP‑seq) is essential but adds complexity.

Reproducibility crisis in bioinformatics. Different pipelines can yield divergent results from the same raw data. Therefore, always document version numbers of all software, use containerized environments (e.g., Docker, Singularity), and share analysis code and configurations.

Frequently Asked Questions

1. What is the difference between whole‑genome sequencing and whole‑exome sequencing? Whole‑genome sequencing covers nearly the entire DNA sequence, including intronic and intergenic regions. Whole‑exome sequencing targets only the protein‑coding exons (about 1.5% of the genome). Exome sequencing is cheaper and easier to interpret, but it misses regulatory and non‑coding variants that may be important in complex diseases.

2. How do I choose between RNA‑seq and microarray for transcriptomics? RNA‑seq provides a broader dynamic range, detects novel transcripts and splice isoforms, and can quantify non‑coding RNAs. Microarrays are limited to predefined probes and have lower sensitivity for low‑expression genes. Choose RNA‑seq if discovery or quantification of unknown transcripts is needed, choose microarrays for well‑characterized targets with a need for lower computational cost.

3. Can I use public sequencing data for my own analysis? Yes. The NCBI Sequence Read Archive (SRA) and other repositories (e.g., European Genome‑phenome Archive) contain vast amounts of publicly available data. You can download FASTQ or BAM files and re‑analyze them, but be aware of consent restrictions and data access policies. Always check the original study’s data use agreement.

4. What quality metrics should I report for a genomics study? Report the sequencing platform, read length, mean coverage depth, percentage of reads mapped, duplication rate, and transition/transversion ratio for DNA‑seq. For RNA‑seq, report the number of genes detected, mapping rate to the transcriptome, and median insert size. These metrics allow others to assess the reliability of your data.

References and Further Reading

Related Articles